1. US Food and Drug Administration. Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. March 2004. Available at https://doi.org/www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
2. US Food and Drug Administration. Innovation/Stagnation: Critical Path Opportunity List. March 2006. Available at https://doi.org/www.fda.gov/oc/initia-tives/criticalpath/reports/opplist.pdf.
3. European Medicines Agency. Mandate of the EMEA Innovation Task Force (ITF). London, April 2006. Available at https://doi.org/www.emea.europa.eu/pdfs/human/itf/itfmandate.pdf.
4. European Medicines Agency. Innovative Drug Development Approaches—Final Report From the EMEA/CHMP-Think-Tank Group on Innovative Drug Development. London, March 2007. Available at https://doi.org/www.emea.europa.eu/pdfs/human/itf/12731807en.pdf.
5. European Medicines Agency. The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future. London. March 2007. Available at https://doi.org/www.emea.europa.eu/pdfs/general/direct/directory/3416303enF.pdf.